NCT05474729

Minocycline for Chronic Autoimmune Uveitis

The Efficacy and Safety of Minocycline for Chronic Autoimmune Uveitis

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Autoimmune uveitis is one kind of non-infectious, sight-threatening, relapsing and severe ocular disease. Approximately 20%-25% autoimmune uveitis patients suffer from the dilemma of blindness for the chronic and persistent inflammatory state in the eyes, which results in continuous destroy in the structure of the eyes and gradually leads to irreversible damage on visual function. However, it shows limiting efficacy of current treatment including glucocorticoids, immunosuppressant and biologics for chronic autoimmune uveitis. Minocycline has been regarded to have anti-apoptosis and immunemodulatory function for decades and it has been illustrated to be beneficial in several neuro-degenerative and neuro-inflammatory diseases. This trial aims to investigate the efficacy and safety of minocycline for chronic autoimmune uveitis with retinal degenerative changes.

Conditions

• Minocycline
• Uveitis
• Retinal Degeneration

Interventions

Type	Name	Description
DRUG	minocycline	minocycline capsule 100mg per day orally

Timeline

• Start date: 2021-12-01
• Primary completion: 2025-12-31
• Completion: 2026-12-31
• First posted: 2022-07-26
• Last updated: 2023-04-18

Locations

1 site across 1 country: China